PMID- 25043822
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141013
LR  - 20211021
IS  - 1598-2998 (Print)
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Linking)
VI  - 46
IP  - 4
DP  - 2014 Oct
TI  - Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in 
      Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study.
PG  - 331-8
LID - 10.4143/crt.2013.130 [doi]
AB  - PURPOSE: To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing 
      sleep disturbance and relieving cancer pain. MATERIALS AND METHODS: One hundred 
      twenty cancer patients with pain (numeric rating scale [NRS] >/= 4) and sleep 
      disturbance (NRS >/= 4) were evaluated. The initial HM-OROS dosing was based on 
      previous opioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study 
      drug was permitted at the investigator's discretion. Pain intensity, number of 
      breakthrough pain episodes, and quality of sleep were evaluated. RESULTS: A total 
      of 120 patients received at least one dose of HM-OROS; 74 of them completed the 
      final assessment. Compared to the previous opioids, HM-OROS reduced the average 
      pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), 
      sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain 
      at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use 
      for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 
      0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they 
      preferred HM-OROS to the previous medication. The adverse events (AEs) were 
      somnolence, asthenia, constipation, dizziness, and nausea. CONCLUSION: HM-OROS 
      was efficacious in reducing cancer pain and associated sleep disturbances. The 
      AEs were manageable.
FAU - Shin, Seong Hoon
AU  - Shin SH
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Kosin University 
      Gospel Hospital, Busan, Korea.
FAU - Lee, Ho Sup
AU  - Lee HS
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Kosin University 
      Gospel Hospital, Busan, Korea.
FAU - Kim, Yang Soo
AU  - Kim YS
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Kosin University 
      Gospel Hospital, Busan, Korea.
FAU - Choi, Young Jin
AU  - Choi YJ
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Pusan National 
      University Hospital, Pusan National University School of Medicine, Busan, Korea.
FAU - Kim, Sung Hyun
AU  - Kim SH
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan National University School of Medicine, 
      Yangsan, Korea.
FAU - Kwon, Hyuk Chan
AU  - Kwon HC
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Dong-A University 
      Hospital, Dong-A University College of Medicine, Busan, Korea.
FAU - Oh, Sung Yong
AU  - Oh SY
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Dong-A University 
      Hospital, Dong-A University College of Medicine, Busan, Korea.
FAU - Kang, Jung Hun
AU  - Kang JH
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Gyeongsang National 
      University Hospital, Gyeongsang National University School of Medicine, Jinju, 
      Korea.
FAU - Sohn, Chang Hak
AU  - Sohn CH
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Inje University 
      Paik Hospital, Inje University College of Medicine, Busan, Korea.
FAU - Lee, Sang Min
AU  - Lee SM
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Inje University 
      Paik Hospital, Inje University College of Medicine, Busan, Korea.
FAU - Baek, Jin Ho
AU  - Baek JH
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Ulsan University 
      Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
FAU - Min, Young Joo
AU  - Min YJ
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Ulsan University 
      Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
FAU - Kim, Choongrak
AU  - Kim C
AD  - Departments of Statistics, National Research Laboratory for Computational 
      Proteomics and Biophysics, Pusan National University, Busan, Korea ; Departments 
      of Physics, National Research Laboratory for Computational Proteomics and 
      Biophysics, Pusan National University, Busan, Korea ; Interdisciplinary Research 
      Program of Bioinformatics, Pusan National University, Busan, Korea.
FAU - Chung, Joo Seop
AU  - Chung JS
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Pusan National 
      University Hospital, Pusan National University School of Medicine, Busan, Korea.
LA  - eng
PT  - Journal Article
DEP - 20140721
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
PMC - PMC4206066
OTO - NOTNLM
OT  - Cancer pain
OT  - Hydromorphone-OROS (HM-OROS)
OT  - Sleep disturbance
COIS- Conflict of interest relevant to this article was not reported.
EDAT- 2014/07/22 06:00
MHDA- 2014/07/22 06:01
PMCR- 2014/10/01
CRDT- 2014/07/22 06:00
PHST- 2013/08/01 00:00 [received]
PHST- 2013/11/01 00:00 [accepted]
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2014/07/22 06:01 [medline]
PHST- 2014/10/01 00:00 [pmc-release]
AID - crt.2013.130 [pii]
AID - crt-2013-130 [pii]
AID - 10.4143/crt.2013.130 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2014 Oct;46(4):331-8. doi: 10.4143/crt.2013.130. Epub 2014 Jul 
      21.